184 results
Page 4 of 10
8-K
EX-99.1
3d63cc3u4l r9szc7fcp
18 May 21
Aravive Announces Three New Appointments to its Board of Directors
7:05am
8-K
qathckeu79b yoie
18 May 21
Aravive Announces Three New Appointments to its Board of Directors
7:05am
8-K
EX-99.2
0plknjxqp5mf6bi0oxl
6 May 21
Aravive continues to expand development of AVB-500 in multiple indications and combination treatments with first-line treatment for pancreatic cancer
7:08am
8-K
EX-99.1
rd2zjlw1vx44g2x
27 Apr 21
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-99.2
6nz5zh02s8o9p4 nqir
27 Apr 21
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-99.1
dnyvzghuh0vb59rcs0k
2 Mar 21
Regulation FD Disclosure
8:00am
424B5
v816txhrn cx
16 Feb 21
Prospectus supplement for primary offering
7:05am
8-K
EX-10.1
aqnf4swu0
4 Jan 21
Aravive Announces Board Member Transition to Advisory Role
4:11pm
8-K
EX-99.2
ebxpda
19 Nov 20
Aravive Announces Phase 3 Trial Design for AVB-500 in Platinum Resistant Ovarian Cancer
7:10am
8-K
yn6uj4lc
10 Nov 20
Entry into a Material Definitive Agreement
7:10am
8-K
EX-10.1
jec0tnhuho9r130fnhe
10 Nov 20
Entry into a Material Definitive Agreement
7:10am
UPLOAD
zzn455 tqm
11 Sep 20
Letter from SEC
12:00am